Neuphoria Therapeutics Inc. Common Stock (NEUP)
PHARMACEUTICAL PREPARATIONS
Neuphoria Therapeutics Inc. Common Stock (NEUP) is listed on Nasdaq, where it has traded since December 16, 2021.
- Listed On
- Nasdaq
- Listed Since
- December 16, 2021
- Employees
- 1
- Market Cap
- $15M
About Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 21 institutions reported holding NEUP, with 2.0 million shares worth $8.7 million in aggregate. The largest reported holder was Lynx1 Capital Management, with 875,328 shares worth $3.8 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Lynx1 Capital Management | 875,328 | $4M | Unchanged |
| Advisorshares Investments | 252,909 | $1M | Added 62.78% |
| Vanguard | 207,294 | $906K | Added 56.92% |
| Shay Capital | 155,822 | $681K | Added 3.19% |
| Balyasny Asset Management | 142,228 | $622K | Added 0.03% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is NEUP?
Neuphoria Therapeutics Inc. Common Stock (NEUP) is listed on Nasdaq, where it has traded since December 16, 2021.
Who are the largest institutional holders of NEUP?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NEUP were Lynx1 Capital Management, Advisorshares Investments and Vanguard.
How many institutions own NEUP?
21 institutions reported a position in NEUP for the quarter ended June 30, 2026, worth $8.7 million in total.
Did institutions buy or sell NEUP last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for NEUP.
Every reported institutional holder, plus insider and congressional trades in NEUP, on SentiSense.